Early Detection of Gestational Diabetes Mellitus in Pregnancy
- Conditions
- Gestational Diabetes Mellitus in PregnancyPregnancy, High Risk
- Registration Number
- NCT05388643
- Lead Sponsor
- University of Massachusetts, Worcester
- Brief Summary
The purpose of this study is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of gestational diabetes mellitus (GDM).
- Detailed Description
Gestational diabetes mellitus (GDM) is an important contributor to both maternal and neonatal morbidity and mortality in pregnancy. GDM has lifelong complications including an increased risk of developing type 2 diabetes mellitus and cardiovascular disease for women, and their offspring are at higher risk of being obese and also having diabetes in childhood and adolescence. Approximately 1 in 8 pregnancies is impacted by gestational diabetes mellitus worldwide. First trimester GDM screening is varied due to conflicting national guidelines, and the best strategy is unknown. The goal of the proposed research is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of GDM. The investigators will utilize a pilot randomized controlled trial to recruit 80 high-risk pregnant women in the first trimester, of whom half will receive protocolized early GDM screening with serum biomarkers before 12 weeks and the remaining half will receive the current standard of care with screening between 24 and 28 weeks of gestation with possible early screening based on provider discretion.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 80
-
- age greater than or equal to 18 years old,
-
- singleton gestation less than or equal to 12 weeks at initial obstetric visit,
-
- receiving prenatal care at UMMHC and plans to deliver at UMMHC,
-
- able and willing to provide informed consent,
-
- English or Spanish speaking, and
-
- are at high risk for developing GDM by ACOG clinical risk factor guidelines.
-
- known diagnosis of pre-existing pregestational diabetes,
-
- plan to receive prenatal care or deliver outside of UMMHC,
-
- inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test), or
-
- systemic steroid use.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Gestational Diabetes Mellitus In pregnancy (24-28 weeks gestation) Confirmed diagnosis of GDM based on 3 hour 100 gram glucose tolerance test
- Secondary Outcome Measures
Name Time Method Neonatal Birthweight At Birth Neonatal Birthweight
Number of participants with brachial plexus injury At Birth Number of participants with brachial plexus injury
APGAR Score At Birth APGAR Score (range 0 to 10, with 10 being the best)
Neonatal Intensive Care Unit Admission At delivery and within first 2 days of life Admission to Level 2 or greater neonatal ICU and length of stay
Mode of Delivery At Birth Mode of delivery (Vaginal versus Cesarean delivery)
Gestational Age at Delivery At Birth Gestational Age at Delivery
Number of Participants with Shoulder Dystocia At Birth Number of Participants with Shoulder Dystocia
Patient Satisfaction with Diabetes Screening Method Postpartum day 1 after birth This will be assessed by the Patient Satisfaction Survey questionnaire, which is scored out of 30, with 30 being the highest score)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of Massachusetts Memorial Medical Center
🇺🇸Worcester, Massachusetts, United States
University of Massachusetts Memorial Medical Center🇺🇸Worcester, Massachusetts, United States